Quantbot Technologies LP Replimune Group, Inc. Transaction History

Quantbot Technologies LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	BUY	$6.87 - $9.31 $11,679 - $15,827	1,700 Added 53.13%	4,900 $40,000
Q4 2023 Feb 14, 2024	BUY	$6.75 - $16.18 $21,600 - $51,776	3,200 New	3,200 $26,000
Q4 2022 Feb 13, 2023	BUY	$17.09 - $27.91 $249,907 - $408,127	14,623 New	14,623 $397,000
Q2 2022 Aug 09, 2022	BUY	$13.32 - $19.98 $66,333 - $99,500	4,980 Added 498.0%	5,980 $104,000
Q1 2022 May 16, 2022	BUY	$15.24 - $29.75 $6,096 - $11,900	400 Added 66.67%	1,000 $16,000
Q4 2021 Feb 11, 2022	BUY	$25.43 - $34.25 $15,258 - $20,550	600 New	600 $16,000
Q3 2021 Nov 09, 2021	SELL	$28.98 - $39.54 $40,572 - $55,356	-1,400 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$28.5 - $39.37 $39,900 - $55,118	1,400 New	1,400 $53,000

149

68M

52.3K

80.3K

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $694M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

Stay updated on Quantbot Technologies LP with notifications on news.